达拉非尼和曲美替尼用于BRAFV600E突变型胶质瘤
Dabrafenib and trametinib in BRAFV600E mutated glioma.
作者信息
Brown Nicholas F, Carter Thomas, Kitchen Neil, Mulholland Paul
机构信息
Department of Oncology, University College London Hospitals, 250 Euston Road, London, NW1 2PG, UK.
UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6DD, UK.
出版信息
CNS Oncol. 2017 Oct;6(4):291-296. doi: 10.2217/cns-2017-0006. Epub 2017 Oct 6.
Abstract
BRAFV600E mutations have been identified in a number of glioma subtypes, most frequently in pleomorphic xanthoastrocytoma, ganglioglioma, pilocytic astrocytoma, and epithelioid glioblastoma. Although the development of BRAF inhibitors has dramatically improved the clinical outcome for patients with BRAFV600E mutant tumors, resistance develops in a majority of patients due to reactivation of the MAPK pathway. Addition of MEK inhibition to BRAF inhibition improves survival. Here we report successful treatment of two patients with BRAFV600E mutant pleomorphic xanthoastrocytoma using the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib.
摘要
在多种胶质瘤亚型中已鉴定出BRAFV600E突变，最常见于多形性黄色星形细胞瘤、节细胞胶质瘤、毛细胞型星形细胞瘤和上皮样胶质母细胞瘤。尽管BRAF抑制剂的开发显著改善了BRAFV600E突变肿瘤患者的临床结局，但由于MAPK通路的重新激活，大多数患者会产生耐药性。在BRAF抑制的基础上加用MEK抑制可提高生存率。在此，我们报告了使用BRAF抑制剂达拉非尼联合MEK抑制剂曲美替尼成功治疗两名BRAFV600E突变多形性黄色星形细胞瘤患者的病例。
相似文献
1
Dabrafenib and trametinib in BRAFV600E mutated glioma.达拉非尼和曲美替尼用于BRAFV600E突变型胶质瘤
CNS Oncol. 2017 Oct;6(4):291-296. doi: 10.2217/cns-2017-0006. Epub 2017 Oct 6.
2
Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.对不耐用维莫非尼的 BRAF V600E 突变的间变性 ganglioglioma 青少年使用 BRAF/MEK 抑制剂 dabrafenib/trametinib 的反应。
Pediatr Blood Cancer. 2018 May;65(5):e26969. doi: 10.1002/pbc.26969. Epub 2018 Jan 30.
3
Dabrafenib plus trametinib in patients with BRAF-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.达拉非尼联合曲美替尼治疗 BRAF 突变型低级别和高级别胶质瘤患者（ROAR）：一项多中心、开放标签、单臂、2 期、篮子试验。
Lancet Oncol. 2022 Jan;23(1):53-64. doi: 10.1016/S1470-2045(21)00578-7. Epub 2021 Nov 24.
4
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.达拉非尼联合曲美替尼，或单药用于治疗 BRAF 突变型转移性黑色素瘤。
Clin Cancer Res. 2014 Apr 15;20(8):2035-43. doi: 10.1158/1078-0432.CCR-13-2054. Epub 2014 Feb 28.
5
Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma.一名播散性间变性多形性黄色星形细胞瘤患者对靶向治疗的持续反应
J Pediatr Hematol Oncol. 2018 Aug;40(6):478-482. doi: 10.1097/MPH.0000000000001032.
6
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.达拉非尼联合曲美替尼治疗 BRAF 和 MEK 抑制剂预处理的晚期 BRAF 突变型黑色素瘤患者：一项开放标签、单臂、双中心、Ⅱ期临床研究。
Lancet Oncol. 2017 Apr;18(4):464-472. doi: 10.1016/S1470-2045(17)30171-7. Epub 2017 Mar 4.
7
Anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination responsive to BRAF inhibition and bevacizumab.具有软脑膜播散的间变性多形性黄色瘤型星形细胞瘤对BRAF抑制和贝伐单抗治疗有效。
Pediatr Blood Cancer. 2019 Jan;66(1):e27465. doi: 10.1002/pbc.27465. Epub 2018 Sep 25.
8
Challenges of targeting V600E mutations in adult primary brain tumor patients: a report of two cases.成人原发性脑肿瘤患者中靶向V600E突变的挑战：两例报告
CNS Oncol. 2019 Dec 1;8(4):CNS48. doi: 10.2217/cns-2019-0018. Epub 2019 Dec 10.
9
Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer.达拉非尼联合曲美替尼治疗转移性 BRAFV600E 突变型甲状腺癌患者。
Cancer Res Treat. 2024 Oct;56(4):1270-1276. doi: 10.4143/crt.2023.1278. Epub 2024 Mar 6.
10
Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.BRAF 突变型黑色素瘤脑转移患者中 BRAF 抑制和 MEK 抑制的临床及影像学反应
Melanoma Res. 2018 Apr;28(2):126-133. doi: 10.1097/CMR.0000000000000429.
引用本文的文献
1
BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications.实体瘤中的BRAF靶向治疗：分子层面与临床应用
Int J Mol Sci. 2025 Apr 16;26(8):3757. doi: 10.3390/ijms26083757.
2
Prognostic Biomarkers in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Focus on B7-H3.异柠檬酸脱氢酶野生型胶质母细胞瘤的预后生物标志物：聚焦于B7-H3
Brain Sci. 2025 Feb 19;15(2):212. doi: 10.3390/brainsci15020212.
3
BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country.BRAF/MEK抑制剂在儿童胶质瘤中的应用；来自资源有限国家的真实世界经验。
Front Oncol. 2024 Sep 27;14:1417484. doi: 10.3389/fonc.2024.1417484. eCollection 2024.
4
Clinicopathological, immunohistochemical and therapeutic approaches on survival in patients with epithelioid glioblastoma: Institutional experience in the management of 58 patients.上皮样胶质母细胞瘤患者的临床病理、免疫组织化学和治疗方法对生存的影响：机构管理 58 例患者的经验。
Neurosurg Rev. 2024 Oct 9;47(1):763. doi: 10.1007/s10143-024-02957-1.
5
The effects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis.达拉非尼联合曲美替尼治疗 BRAF V600 突变型脑胶质瘤的疗效：系统评价和荟萃分析。
Neurosurg Rev. 2024 Aug 22;47(1):458. doi: 10.1007/s10143-024-02664-x.
6
Canadian Consensus for Treatment of BRAF Mutated Pediatric and AYA Gliomas.加拿大 BRAF 突变型儿科和青少年胶质瘤治疗共识。
Curr Oncol. 2024 Jul 16;31(7):4022-4029. doi: 10.3390/curroncol31070299.
7
Advances in Molecular Pathology, Diagnosis and Treatment of Spinal Cord Astrocytomas.脊髓星形细胞瘤的分子病理学、诊断和治疗进展。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241262483. doi: 10.1177/15330338241262483.
8
The potential of liquid biopsy for detection of the KIAA1549-BRAF fusion in circulating tumor DNA from children with pilocytic astrocytoma.液体活检在检测儿童毛细胞型星形细胞瘤循环肿瘤DNA中KIAA1549-BRAF融合的潜力。
Neurooncol Adv. 2024 Jan 24;6(1):vdae008. doi: 10.1093/noajnl/vdae008. eCollection 2024 Jan-Dec.
9
Predicting the molecular mechanism-driven progression of breast cancer through comprehensive network pharmacology and molecular docking approach.通过综合网络药理学和分子对接方法预测乳腺癌的分子机制驱动进展。
Sci Rep. 2023 Aug 22;13(1):13729. doi: 10.1038/s41598-023-40684-7.
10
TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report.肿瘤电场疗法延长上皮样胶质母细胞瘤患者的无进展生存期：一例报告
Brain Sci. 2023 Apr 7;13(4):633. doi: 10.3390/brainsci13040633.
本文引用的文献
1
BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma.BRAF/MEK双重阻断治疗难治性间变性多形性黄色星形细胞瘤
Neurology. 2017 Mar 28;88(13):1291-1293. doi: 10.1212/WNL.0000000000003767. Epub 2017 Feb 24.
2
Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.达拉非尼用于BRAFV600突变的间变性多形性黄色星形细胞瘤
CNS Oncol. 2017 Jan;6(1):5-9. doi: 10.2217/cns-2016-0031. Epub 2016 Oct 26.
3
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.在一种新型同基因小鼠胶质瘤模型中，同时进行的MEK靶向治疗可防止BRAFV600E靶向抑制期间MAPK通路的重新激活。
Oncotarget. 2016 Nov 15;7(46):75839-75853. doi: 10.18632/oncotarget.12419.
4
Primary cerebral malignant melanoma in insular region with extracranial metastasis: case report and review literature.岛叶原发性脑恶性黑色素瘤伴颅外转移：病例报告及文献复习
World J Surg Oncol. 2016 Sep 1;14(1):235. doi: 10.1186/s12957-016-0965-7.
5
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.2016 年世界卫生组织中枢神经系统肿瘤分类：概述。
Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.
6
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.BRAF V600E突变型乳头状颅咽管瘤对靶向治疗的显著反应
J Natl Cancer Inst. 2015 Oct 23;108(2). doi: 10.1093/jnci/djv310. Print 2016 Feb.
7
Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib.具有间变特征的原发性脑膜多形性黄色星形细胞瘤：2例报告，其中1例存在BRAF（V600E）突变并对BRAF抑制剂达拉非尼有临床反应
J Neuropathol Exp Neurol. 2015 Oct;74(10):960-9. doi: 10.1097/NEN.0000000000000240.
8
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.维莫非尼用于治疗伴有BRAF V600突变的多种非黑色素瘤癌症。
N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.
9
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.BRAF 抑制剂单独及联合 MEK 抑制剂治疗转移性黑色素瘤的皮肤毒性作用。
JAMA Dermatol. 2015 Oct;151(10):1103-9. doi: 10.1001/jamadermatol.2015.1745.
10
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.达拉非尼联合曲美替尼与达拉非尼联合安慰剂治疗 Val600BRAF 突变型黑色素瘤：一项多中心、双盲、III 期随机对照临床试验。
Lancet. 2015 Aug 1;386(9992):444-51. doi: 10.1016/S0140-6736(15)60898-4. Epub 2015 May 31.
Zotero 插件